

**Table 1.1 Therapeutic monoclonal antibodies, Fc fusion and Fab conjugates approved or in review in the European Union or United States<sup>a</sup>—cont'd**

Brand name	Molecule	Type of mAb	Year approved	Company	Indication	Administration route
Removab	Catumaxomab	Anti-EPCAM/CD3; rat/murine bispecific mAb	2009 (NA)	Trion Pharma	Malignant ascites	IV infusion
ReoPro	Abciximab	Anti-glycoprotein IIb/IIIa receptor; chimeric Fab	1995 (1994)	Centocor and Lilly	Reduction of acute blood clot-related complications	IV injection and infusion
Rituxan	Rituximab	Anti-CD20; chimeric IgG1κ	1998 (1997)	IDEC and Genentech	Non-Hodgkin's lymphoma	IV infusion
Scintimun	Besilesomab	Anti-NCA-95 found on surface of granulocytes; murine mAb	2010	CIS Bio International	In vivo diagnosis/investigation of sites of inflammation/infection via scintigraphic imaging	IV
Simponi	Golimumab	Anti-TNFα; human IgG1	2009 (2009)	Centocor	Rheumatoid and psoriatic arthritis, ankylosing spondylitis	SC
Simulect	Basiliximab	Anti-IL2; chimeric IgG1κ	1998 (1998)	Novartis	Prevention of acute kidney transplant rejection	IV injection and infusion
Soliris	Eculizumab	Humanized IgG2/IgG4	2007 (2007)	Alexion	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	IV infusion
Stelara	Ustekinumab	Anti-IL2/23; human IgG1	2009 (2009)	Janssen Biotech/Centocor	Psoriasis	SC
Sylvant	Siltuximab	Anti-IL-6; chimeric IgG1	2014	Janssen Biotech, Inc.	Castleman disease	IV
Synagis	Palivizumab	Anti-protein F of RSV; humanized IgG1κ	1999 (1998)	Medimmune	Respiratory tract disease caused by respiratory syncytial virus (RSV)	IM